

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for alleviating a ~~treating a urological-neurological~~ symptom of ~~a patient with~~ prostate cancer, the method comprising the step of administering a therapeutic amount of a botulinum toxin into the prostate gland of a patient with prostate cancer, thereby alleviating a symptom of prostate cancer ~~or its treatment~~.
2. (Cancelled)
3. (Currently Amended) The method of claim 1, wherein the symptom of prostate cancer ~~prostate cancer treatment~~ is selected from the group consisting of urinary incontinence, urinary retention, urge-type dysfunction, unstable bladder, unstable sphincter, and recurrent urinary infection.
4. (Original) The method of claim 1, wherein the symptom of prostate cancer is urinary incontinence.
5. (Original) The method according to claim 1, where the patient is a human male.
6. (Original) The method according to claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F, and botulinum toxin type G.
7. (Original) The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.
8. (Original) The method of claim 1, wherein the botulinum toxin is botulinum toxin type B.
9. (Original) The method of claim 1, wherein the step of administering comprises injecting.
10. (Currently amended) A method for alleviating a ~~treating a urological-neurological~~ symptom ~~in a patient with~~ of prostate cancer, the method comprising the step of administering a therapeutic amount of a botulinum toxin into a portion of the lower urinary tract of a patient with prostate cancer, thereby alleviating a symptom of prostate cancer ~~or its treatment~~.
11. (Original) The method of claim 10, wherein the symptom is pelvic pain.

12. (Cancelled)
13. (Original) The method of claim 10, wherein the symptom is selected from the group consisting of urinary incontinence, urinary retention, urge-type dysfunction, unstable bladder, unstable sphincter, and recurrent urinary infection.
14. (Cancelled)
15. (Original) The method according to claim 10, where the patient is a human male.
16. (Original) The method according to claim 10, wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F, and botulinum toxin type G.
17. (Original) The method of claim 10, wherein the botulinum toxin is botulinum toxin type A.
18. (Original) The method of claim 10, wherein the portion of the lower urinary tract is selected from the group consisting of the bladder, the external urethral sphincter, and the bladder neck.
19. (Original) The method of claim 10, wherein the step of administering comprises injecting.
20. (New) The method of claim 1, wherein the symptom is prostatic enlargement.
21. (New) The method of claim 10, wherein the symptom is prostatic enlargement.